WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA® (finerenone) in heart failure (HF) patients with a left ventricular ejection fraction (LVEF) of ≥40%, in a Featured Science session at the American Heart Association (AHA) Scientific Sessions 2024, taking place in Chicago, IL, from November 16-18, 2024.
KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for HF, non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).1
Presentations at AHA 2024 include:
- Effect of Finerenone on a Hierarchical Composite Endpoint Analyzed Using Win Statistics in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF
- Session: Featured Science: Getting Closer to the Summit
- November 17, 2024, 08:10 am (CST) / 09:10 am (EST)
The primary outcomes of FINEARTS-HF were analyzed using a win ratio approach, to allow for analysis according to their clinical importance in the following order: cardiovascular death (Tier 1); total HF hospitalizations (taking account of both the number of events and time to event) (Tier 2); and total urgent HF visits (Tier 3).
- Efficacy and Safety of Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Sex-Specific Analysis of the FINEARTS-HF Trial
- Session: Featured Science: Getting Closer to the Summit
- November 17, 2024, 08:20 am (CST) / 09:20 am (EST)
Recognizing sex-related differences in the clinical presentation, symptoms and quality of life, prognosis, and treatment response in HF, this prespecified analysis evaluated the efficacy and safety of finerenone for HF with LVEF ≥40% in both women and men.
- Finerenone and Risk of Hyperkalemia in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Session: Featured Science: Getting Closer to the Summit
- November 17, 2024, 08:30 am (CST) / 09:30 am (EST)
This prespecified analysis investigated the frequency and predictors of hyperkalemia and examined the treatment effect of finerenone, relative to placebo, on clinical outcomes based on post-randomization potassium levels.